SCYX NASDAQ
SCYNEXIS, Inc.
1W: +16.6%
1M: -1.9%
3M: +8.2%
YTD: +701.9%
1Y: +533.4%
3Y: +142.7%
5Y: -8.2%
$5.12
-0.25 (-4.66%)
Weekly Expected Move ±11.7%
$4
$5
$5
$6
$6
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
4 relationships4
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2023-03-30
Earliest Filing
2026-03-31
Latest Filing
partner: 3
target: 1
Counterparties (Filed by SCYX)
4 relationshipsCompanies named in SCYX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Poxel SA | — | target | Acquired AMP kinase activator research and development program assets and intellectual property license. | 2026-03-31 | View |
| GlaxoSmithKline Intellectual Property (No. 3) Limited | — | partner | Partnered with SCYNEXIS to amend exclusive license agreement and resolve MARIO Study disagreement. | 2025-10-15 | View |
| GlaxoSmithKline Intellectual Property (No. 3) Limited | — | partner | Entered into a binding MOU to amend an exclusive license agreement for the development and commercialization of ibrexafu | 2024-01-02 | View |
| GlaxoSmithKline Intellectual Property (No. 3) Limited | — | partner | Licensee for development, manufacture, and commercialization of ibrexafungerp | 2023-03-30 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-28 | Material Agreement; Regulation FD; Exhibits | Agreement | View |
| 2026-09-22 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-09-10 | Officer/Director Change; Other Events | View | |
| 2026-06-26 | Bylaws Amendment; Shareholder Vote; Other Events; Exhibits | View | |
| 2026-05-29 | Bylaws Amendment; Exhibits | View | |
| 2026-05-22 | Shareholder Vote; Other Events | View | |
| 2026-04-20 | Officer/Director Change | View | |
| 2026-03-31 | Material Agreement; Acquisition/Disposition; Regulation FD; Exhibits | Agreement Acquisition | View |
| 2026-03-31 | Material Agreement; Unregistered Equity Sales; Regulation FD; Other Events; Exhibits | Agreement | View |
| 2026-03-31 | Regulation FD; Exhibits | View | |
| 2025-10-15 | Entry into Material Definitive Agreement | Agreement | View |
| 2025-07-01 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-06-26 | Notice of Delisting or Transfer | View | |
| 2024-11-06 | Other Events; Financial Statements and Exhibits | View | |
| 2024-09-10 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2024-03-28 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-01-05 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2024-01-02 | Entry into Material Definitive Agreement | Agreement | View |
| 2023-10-02 | Other Events | View | |
| 2023-09-25 | Other Events | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR